期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

化疗联用序贯厄洛替尼治疗转移脑肿瘤一例及文献复习

下载PDF
导出
摘要 治疗伴脑转移的非小细胞肺癌（non—small lung cancer，NSCLC）的全身化疗药物因不能有效地透过血脑屏障而治疗效果差。近年来，随着表皮生长因子受体（epidermal growth factor receptor，EGFR）小分子抑制剂厄洛替尼（erlotinib）的问世，对伴脑转移的NSCLC的治疗取得了一定的疗效。本文报道采用化疗[培美曲塞＋（DDP）顺铂]序贯厄洛替尼治疗1例PS评分较差的转移脑肿瘤、取得较好疗效且患者耐受性好，并结合文献进行讨论。
作者 郭水英 邹海萍 常建华
机构地区 上海市徐汇区中心医院肿瘤科 复旦大学附属肿瘤医院化疗科、复旦大学上海医学院肿瘤学系
出处 《中国癌症杂志》 CAS CSCD 2008年第12期958-960,共3页 China Oncology
关键词 化疗 靶向治疗 脑转移瘤
分类号 R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Davies AM, Ho C, Lara PN Jr, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small cell lung cancer [ J ] . Clin Lung Cancer, 2006, 7: 385-388.
  • 2Lee JS, Ignacio J,Yu C,et al. FAST-ACT: A phase Ⅱ randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage m B/Ⅳ non-small cell lung cancer (NSCLC) [J]. J Clin Oncol, 2008, 26 (Suppl.): abstr 8031.
  • 3Allan SG, Bosquee L, Franke A. Efficacy of erlotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) relative to clinical characteristics:subset analyses from the TRUST study[J].J Clin Oncol, 2008, 26(Suppl.): Abstr.8081
  • 4Scagliotti G, Purvish P, Von Pawel, et al. Phase Ⅲ study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer(NSCLC) [ J ] . J Thoracic Oncol, 2007, 2(8 Suppl 4): S306.
  • 5陈闪闪,冯奉仪.培美曲塞在非小细胞肺癌治疗中的研究进展[J].肿瘤学杂志,2007,13(1):22-25. 被引量：7
  • 6Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small cell lung cancer:a prospective trial [J].Ann Oncol, 2004, 15(7): 1042-1047.
  • 7Hotta K, Kiura K, Ueoka H,et al. Effect of gefitinib ( 'Iressa' ,ZD1839) on brain metastases in patients with advanced non-small cell lung cancer [ J ] . Lung Cancer, 2004, 46(2): 255-261.
  • 8Shimato S, Mitsudomi T, Kosaka T et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib [ J ] . Neuro Oncol, 2006, 8(2): 137-144.
  • 9Pan M,Santamaria M,Wollman DB. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation [ J ] . Nat Clin Pract Oncol, 2007, 4(10):603- 607.
  • 10Cedr e s S, Prat A, Felip E, et al. Cutaneous rash as a surrogate marker of time to tumor progression (TTP) with erlolinib in previously treated advanced non-small cell lung cancer (NSCLC) [ J ] . J Clin Oncol, 2008, 26 (Suppl.): Abstr. 19125.

二级参考文献18

  • 1Rusthoven JJ,Eisenhauer E,Butts C,et al.Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer:A phase Ⅱ study.National Cancer Institute of Canada Clinical Trails Group[J].J Clin Oncol,1999,17:1194.
  • 2Clarke SJ,Abratt R,Goedhals L,et al.Phase Ⅱ trial of pemetrexed disodium (ALIMTA,LY231514) in chemotherapy-na(i)ve patients with advanced non-small-cell lung cancer[J].Ann Oncol,2002,13(5):737-741.
  • 3Smit EF,Mattson K,yon Pawel J,et al.ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer:a phase Ⅱ study[J].Ann Oncol,2003,14(3):455-460.
  • 4Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589-1597.
  • 5Manegold C,Gatzemeier U,yon Pawel J,et al.Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514,pemetrexed disodium,ALIMTA) and cisplatin:a multicenter phase Ⅱ trial[J].Ann Oncol,2000,11(4):435-440.
  • 6Shepherd FA,Dancey J,Arnold A,et al.Phase Ⅱ study of pemetrexed disodium,a multitargeted antifolate,and cisplatin as first-line therapy in patients with advanced non-small-cell lung carcinoma:a study of the National Cancer Institute of Canada Clinical Trails Group[J].Cancer,2001,92:595-600.
  • 7Scagliotti GV,Kortsik C,Dark GG,et al.Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment inadvanced non-small cell lung cancer:a multicenter,randomized,phase Ⅱ trial[J].Clin Cancer Res,2005,11(2 Pt 1):690-696.
  • 8Zinner RG,Fossella FV,Gladish GW,et al.Phase Ⅱ study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer[J].Cancer,2005,104(11):2449-2456.
  • 9Scagliotti GV.Pemetrexed:a new cytotoxic agent in the development for first-line non-small-cell lung cancer[J].Lung Cancer,2005,50 (suppl 1):18-19.
  • 10Monnerat C,Le Chevalier T,Kelly K,et al.Phase Ⅱ study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer[J].Clin Cancer Res,2004,10(16):5439-5446.

共引文献6

中国癌症杂志
2008年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部